Key result
In patients with essential thrombocythemia, CALR mutations were associated with an almost 12-fold higher risk of progression to myelofibrosis compared to JAK2 mutations (HR 11.5).
Population
Patients with Essential thrombocythemia (ET)
Design
Editorial
Authors
Loading...
Predicting thrombosis, progression, and survival in essential thrombocythemia requires retrospective analysis of large cohorts with long follow-up due to the disease's uncommon and heterogeneous nature.
Cohort (n=328)
No
Hazard Ratio: 11.5
p-value: p=0.008
Predicting thrombosis, progression, and survival in essential thrombocythemia requires retrospective analysis of large cohorts with long follow-up due to the disease's uncommon and heterogeneous nature.
Abu‐Zeinah et al. (2024) conducted a cohort in Essential thrombocythemia (n=328). CALR mutation vs. JAK2 mutation was evaluated on Progression to myelofibrosis (HR 11.5, p=0.008). In patients with essential thrombocythemia, CALR mutations were associated with an almost 12-fold higher risk of progression to myelofibrosis compared to JAK2 mutations (HR 11.5).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: